Impact of Antibiotic-Resistant Bacterial and Fungal Infections in Outcome of Acute Pancreatitis

Pancreas. 2018 Apr;47(4):489-494. doi: 10.1097/MPA.0000000000001019.

Abstract

Objectives: The knowledge about pathogens and their antibiotic susceptibility patterns is essential to select an appropriate antibiotic.

Methods: We investigated the microbiological profile in pancreatic and extrapancreatic infections, and antibiotic sensitivity pattern in patients with acute pancreatitis.

Results: Of 556 patients with acute pancreatitis, only 189 developed bacterial infection; however, bacteremia was present in 42 patients (7.6%). Culture-proven infected pancreatic necrotic collection was present in 161 patients (29%). Escherichia coli and Klebsiella pneumoniae were the most common organisms. Among the bacterial infection cohort, 164 patients developed multidrug-resistant bacterial infection. Infection with multidrug-resistant bacteria, especially at multiple sites, increased mortality. Nearly 50% of patients (n = 94) acquired extremely drug-resistant bacterial infection at some time and emerged as key reason for prolonged hospital and intensive care unit stay. Colistin resistance and tigecycline resistance were documented in 2.1% and 17.2% of the specimens at admission and in 4.6% and 21% of specimens during the hospital stay. Of 556 patients, 102 patients developed fungal infection and 28 patients had only fungal infection without bacterial infection.

Conclusions: Colistin and tigecycline are best reserved as last-resort antibiotics. Fungal infection was found to be associated with increased mortality, median hospital stay, and intensive care unit stay.

MeSH terms

  • Acute Disease
  • Adult
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteria / classification
  • Bacteria / drug effects*
  • Bacterial Infections / drug therapy*
  • Bacterial Infections / microbiology
  • Drug Resistance, Microbial
  • Female
  • Humans
  • Intensive Care Units
  • Length of Stay
  • Male
  • Middle Aged
  • Minocycline / analogs & derivatives
  • Minocycline / therapeutic use
  • Mycoses / drug therapy*
  • Mycoses / microbiology
  • Outcome Assessment, Health Care
  • Pancreatitis / drug therapy*
  • Pancreatitis / microbiology
  • Tigecycline

Substances

  • Anti-Bacterial Agents
  • Tigecycline
  • Minocycline